Abstract
Liver metastasis is one of the most important prognostic factors in lung cancer patients. However, current therapies are not sufficient. RNA interference provides us a powerful and promising approach for treating human diseases including cancers. Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer. PLK-1 was overexpressed in cell lines and in cancerous tissues from lung cancer patients. PLK-1 siRNA treatment inhibited growth and induced apoptosis in a concentration-dependent manner. To verify in vivo efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted luciferase-labeled A549LUC cells by detecting reduced bioluminescence after an i.v. injection of luciferase GL3 siRNA/atelocollagen. PLK-1 siRNA/atelocollagen was also successfully transfected into cells and inhibited the progression of metastases. This study shows the efficacy of i.v. administration of PLK-1 siRNA/atelocollagen for liver metastases of lung cancer. We believe siRNA therapy will be a powerful and promising strategy against advanced lung cancer.
Highlights
The discovery of RNA interference [1] led to its wide application as a powerful tool in postgenomic research
We recently showed that Polo-like kinases (PLK)-1 is a prognostic marker of urinary bladder carcinoma and that the intravesical administration of PLK-1 small interfering RNA (siRNA) inhibited the growth of bladder cancer in an orthotopic murine model [15]
We showed that PLK-1 is overexpressed in lung cancer tissues
Summary
The discovery of RNA interference [1] led to its wide application as a powerful tool in postgenomic research. Small interfering RNA (siRNA), which induces RNA interference, has been experimentally introduced into cancer therapy. The establishment of siRNA therapy depends on the development of suitable delivery systems. Several useful drug delivery systems (DDS) for siRNA have been developed (2 – 6). Atelocollagen is one of the most unique and attractive DDS. It was developed as a biomaterial carrier for gene delivery and is obtained from type I collagen of calf dermis using pepsin treatment [3, 7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
